Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aurora Cannabis Inc (ACB) vs Medpace Holdings Inc (MEDP) Price & Performance

Aurora Cannabis IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Aurora Cannabis Inc vs Medpace Holdings Inc — how do they compare? Aurora Cannabis Inc trades at $3.79 (market cap $223.59M), while Medpace Holdings Inc trades at $600.79 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 75.6× Aurora Cannabis Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Aurora Cannabis Inc nearer its low. Which is the better fit depends on your goals.

ACBMEDP
Market Cap
$223.59M$16.90B
Sector
HealthTechnology
52-Week High
$6.23$620.59
52-Week Low
$2.58$393.42
Enterprise Value
$168.09M$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aurora Cannabis Inc

Aurora Cannabis (ACB) trades at $3.79, up 31.14% amid a hostile takeover bid from Curaleaf at $4 per share. The stock shows neutral technical signals with bearish moving averages. Fundamentally, 2025 revenue grew to $343.29M with a slim net profit of $1.59M, but 2026 projections indicate a net loss of $120M. Analyst consensus is mixed with 21.43% buy ratings, reflecting uncertainty over the acquisition offer and standalone prospects.

The outlook hinges on the takeover outcome; acceptance could provide immediate upside, while rejection may pressure shares given weak 2026 forecasts. Key risks include execution challenges, regulatory hurdles, and competitive pressures. Investors face a binary event driving near-term volatility.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aurora Cannabis Inc

Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.

Read more on ACB

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP